Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Paclitaxel in Patients With CLI (Critical Limb Ischemia) and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty

Trial Profile

Evaluation of Paclitaxel in Patients With CLI (Critical Limb Ischemia) and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Chronic limb-threatening ischemia
  • Focus Therapeutic Use

Most Recent Events

  • 23 Apr 2024 Status changed from active, no longer recruiting to completed.
  • 22 Apr 2024 The protocol has been amended to decrease in study time frame for Primary endpoint up to 6 months.
  • 02 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top